Single-centred experience with levosimendan in paediatric decompensated dilated cardiomyopathy

Area of Science:

• Pediatric Cardiology
• Cardiovascular Pharmacology
• Heart Failure Management

Background:

• Children with dilated cardiomyopathy often face prolonged waits for heart transplantation, necessitating mechanical circulatory support.
• Levosimendan, a positive inotropic agent, shows promise in treating pediatric heart failure.

Purpose of the Study:

• To evaluate the clinical experience of using levosimendan in pediatric patients with decompensated dilated cardiomyopathy.

Main Methods:

• Retrospective analysis of pediatric patients with dilated cardiomyopathy awaiting transplantation.
• Levosimendan infusions administered prior to mechanical circulatory support consideration.
• Analysis of biological markers (B-type natriuretic peptide) and echocardiographic parameters (ejection fraction, velocity time integral).

Main Results:

• Significant reduction in B-type natriuretic peptide levels post-infusion (P=0.003).
• Trend towards improved left ventricular ejection fraction (P=0.054-0.068).
• Significant increase in subaortic velocity time integral, indicating improved cardiac output (P=0.041).

Conclusions:

• Levosimendan demonstrates hemodynamic benefits in pediatric decompensated dilated cardiomyopathy.
• Repeated levosimendan infusions may postpone the need for mechanical circulatory support.
• Levosimendan should be considered as an adjunct to standard inotropic therapies in this patient population.